GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

27 Feb 2024 14:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

14 Feb 2024 12:29:34 By Nasdaq GlobeNewswire

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 09:56:04 By Nasdaq GlobeNewswire

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

02 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

01 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

29 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

24 Nov 2023 13:01:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

21 Nov 2023 08:54:48 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

20 Nov 2023 16:03:43 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

25 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference

20 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

12 Sep 2023 09:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire